StroberLBChristodoulouCBenedictRHet al. Unemployment in multiple sclerosis: The contribution of personality and disease. Mult Scler2012; 18: 647–653.
2.
UherTHorakovaDKalincikTet al. Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a. Eur J Neurol2015; 22: 1113–1123.
3.
FilippiMRoccaMABenedictRHet al. The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology2010; 75: 2121–2128.
4.
SumowskiJFBenedictREnzingerCet al. Cognition in multiple sclerosis: State of the field and priorities for the future. Neurology2018; 90: 278–288.
5.
BenedictRHDeLucaJPhillipsGet al. Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis. Mult Scler2017; 23: 721–733.
6.
MorrowSAO’ConnorPWPolmanCHet al. Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler2010; 16: 1385–1392.
7.
BenedictRHMorrowSRodgersJet al. Characterizing cognitive function during relapse in multiple sclerosis. Mult Scler2014; 20: 1745–1752.
DamascenoADamascenoBPCendesF.No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy. Mult Scler2016; 22: 64–72.
10.
CohanSBRDe SezeJHauserSet al. Time to cognitive worsening in patients with relapsing multiple sclerosis in Ocrelizumab phase III trials. Am Acad Neurol2018; 90: S44.
11.
BenedictRH.Impact of siponimod on cognition in patients with secondary progressive multiple sclerosis: Results from phase III EXPAND study. In: Proceedings of the oral presentation at the 70th annual meeting of the American Academy of Neurology, Los Angeles, CA, 21–27 April 2018.
12.
Rae-GrantADayGSMarrieRAet al. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology2018; 90: 789–800.
